Introduction: Myocardial ischemia, brought on by a discrepancy between myocardial perfusion and oxygen demand, is the usual culprit in cases of angina pectoris. Beta-blockers (BBs) and calcium channel blockers (CCBs) are the drugs of choice for initial treatment of stable angina, with other classes of drugs used in case the first two are insufficient. The development of methods to enhance care for patients with chronic stable angina is ongoing. It was anticipated that this systematic review will help quantify the therapeutic benefit of using Ivabradine, Ranolazine, Trimetazidine, and Nicorandil in addition to first-line monotherapy for stable coronary artery disease. Materials and Methods: The PICOS framework, a standardised worldwide method for defining inclusion and exclusion criteria, was used, as indicated by the PRISMA guidelines. Individuals that were a part of the research population. Results: After an initial literature search, 36 out of 45 studies that could be fully analysed were deemed ineligible for further consideration because either they did not provide any results or their entire texts were unavailable. Each of the prescription medications for adjunctive treatment proved to be efficient, risk-free, and well-tolerated. The frequency of angina events decreased, and so did the need for nitrates, suggesting that angina pectoris symptoms had improved. Add-on Trimetazidine is a fast-acting, low-risk method of lowering both angina episodes and nitrate use in the real-world clinical environment. Moreover, it improves physical fitness and overall health. When combined to regular antianginal medication, nicorandil significantly reduced the frequency of ischemia episodes in coronary heart disease (CHD)patients with stable angina. It has a favourable safety profile, with no unexpected adverse effects found. Quality of life(QoL) was shown to improve in individuals with stable angina and coronary artery disease (CAD) when Ivabradine was coupled with metoprolol. The positive effects seen with this combination are likely the cause of its high rate of adherence. Conclusion: The results of the current research indicate that adjunctive therapy is an effective and safe method of lowering the frequency of angina episodes and the need for nitrates. In addition, evidence suggests that therapy for angina should be tailored to each individual patient, their comorbidities, and the underlying cause of their condition.